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Abstract
Mendelian diseases have shown to be an and efficient model for connecting
genotypes to phenotypes and for elucidating the function of genes. Whole‐exome
sequencing (WES) accelerated the study of rare Mendelian diseases in families,
allowing for directly pinpointing rare causal mutations in genic regions without the
need for linkage analysis. However, the low diagnostic rates of 20–30% reported
for multiple WES disease studies point to the need for improved variant
pathogenicity classification and causal variant prioritization methods. Here, we
present the exome Disease Variant Analysis (eDiVA; http://ediva.crg.eu), an
automated computational framework for identification of causal genetic variants
(coding/splicing single‐nucleotide variants and small insertions and deletions) for
rare diseases using WES of families or parent–child trios. eDiVA combines next‐
generation sequencing data analysis, comprehensive functional annotation, and
causal variant prioritization optimized for familial genetic disease studies. eDiVA
features a machine learning‐based variant pathogenicity predictor combining
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various genomic and evolutionary signatures. Clinical information, such as disease
phenotype or mode of inheritance, is incorporated to improve the precision of the
prioritization algorithm. Benchmarking against state‐of‐the‐art competitors
demonstrates that eDiVA consistently performed as a good or better than
existing approach in terms of detection rate and precision. Moreover, we applied
eDiVA to several familial disease cases to demonstrate its clinical applicability.
K E YWORD S
disease variant prioritization, machine learning, NGS diagnostics, rare genetic disease, whole‐
exome sequencing
1 | INTRODUCTION
Rare genetic diseases are classical models for studying gene function and
linking genotypes to disease phenotypes. Although each of these diseases
only affects a small number of patients, the sum of people affected by one
of the more than 7,000 rare diseases exceeds 30 million individuals in the
US alone (Cutting, 2014). Whole‐exome sequencing (WES), and more
recently whole‐genome sequencing (WGS), are routinely applied to
identify variants causing rare Mendelian diseases in studies of families or
parent–child trios (Choi et al., 2009; Ng et al., 2010; Louis‐Dit‐Picard
et al., 2012; Rabbani, Mahdieh, Hosomichi, Nakaoka, & Inoue, 2012).
Usually, each exome sequencing experiment yields tens of
thousands of genetic variants in coding and splicing regions that require
thorough functional annotation and filtering to allow identification of
the causal variant. Several tools have been published performing variant
annotation, including Annovar, VEP, or SNPeff, which augment the
sequencing information with a comprehensive set of current omics,
population genomics, and clinical knowledge (Cingolani et al., 2012;
McLaren et al., 2016; Wang, Li, & Hakonarson, 2010). These tools utilize
a large selection of available databases containing gene annotations,
various genomic features, variant allele frequencies in different
populations, functional impact prediction, and evolutionary conservation
(Bao et al., 2014). Other methods, such as eXtasy (Sifrim et al., 2013),
PhenoDB (Sobreira, Schiettecatte, Boehm, Valle, & Hamosh, 2015),
Phen–Gen (Javed, Agrawal, & Ng, 2014), VarSifter (Teer, Green,
Mullikin, & Biesecker, 2012), KGGseq (M.‐X. Li, Gui, Kwan, Bao, &
Sham, 2012), and SPRING (Wu, Li, & Jiang, 2014), focus on prioritization
of potentially causal variants using both functional annotation and
clinical information. These tools systematically filter, evaluate, and
prioritize thousands of variants, taking into account knowledge found in
genome annotation databases (Rhead et al., 2010), disease gene
repositories (OMIM, Online Mendelian Inheritance in Man; Landrum
et al., 2014), and patient pedigree information, as well as phenotype
descriptions and disease definitions provided for example, as Human
Phenotype Ontology (HPO) terms (Köhler et al., 2014). Finally, methods
such as Endeavour (Tranchevent et al., 2008) and GeneDistiller (Seelow
et al., 2008) prioritize disease genes, not individual variants, by
integrating diverse genomic data sources.
Detection rates of causal variants using WES have been reported to
be as low as 20–30% of cases (H. Lee et al., 2014; Yang et al., 2013),
although higher success rates have been reported for specific disease or
inheritance types (Sawyer et al., 2016) and for studies using parent–
child trios (Yang et al., 2013). While some of the unsolved cases might
be explained by intergenic or intronic regulatory variation or
unidentified structural variants, the low detection rate also indicates
the need for development of better prioritization strategies for coding
variants and robust classifiers comprehensively integrating the available
amount of prior omics and the knowledge of the disease.
Many computational algorithms have been developed to assess
pathogenicity of genetic variants. Tools such as SIFT (Kumar, Henikoff,
& Ng, 2009), CADD (Kircher et al., 2014), PolyPhen‐2 (Adzhubei et al.,
2010), or Eigen (Ionita‐Laza, McCallum, Xu, & Buxbaum, 2016) are
commonly used in clinical practice to help variant interpretation. They
derive a functional impact score based on amino acid or nucleotide
conservation, and biochemical properties of the amino acid changes as
features. While some algorithms additionally categorize variants into
various categories such as “neutral,” “benign,” “deleterious,” “damaging,”
“probably‐damaging,” or “pathogenic” (e.g., SIFT, Condel, PolyPhen‐2,
andMutation Assessor), scores of other methods need to be interpreted
by using (often arbitrary) cutoffs for pathogenicity (e.g., CADD). These
predicted pathogenicity labels are an integral part of the American
College of Medical Genetics and Genomics standards and guidelines for
the interpretation of sequence variants (Richards et al., 2015). Methods
combining multiple classifiers, such as MetaLR, have been shown to
produce better results than single classifiers (Dong et al., 2015).
Recently, specialized ensemble learning methods for estimating
pathogenicity of rare variants have been published: Mendelian Clinically
Applicable Pathogenicity (M‐CAP; Jagadeesh et al., 2016), using
gradient‐boosting trees on pathogenicity scores and conservation
features, and Revel (Ioannidis et al., 2016), using an RF to integrate
several pathogenicity predictors.
To combine an intuitive user interface with comprehensive variant
prediction, annotation, pathogenicity classification, and causal variant
prioritization we developed eDiVA (exome Disease Variant Analysis),
http://www.ediva.crg.eu. The eDiVA pipeline is composed of four main
components: (a) eDiVA‐Predict, where sequencing results are processed
to predict the presence of genomic variants; (b) eDiVA‐Annotate, that
enriches variants via a domain‐knowledge database; (c) eDiVA‐Score,
which estimates variant pathogenicity using a random forest model; and
(d) eDiVA‐Prioritize, in which variants from small groups of related
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samples (i.e., families or parent–child trios) are analyzed jointly. eDiVA
returns a shortlist of candidate variants compatible with the selected
disease inheritance model and the pedigree information. Using the
pathogenicity probability computed by eDiVA‐Score, variants are ranked
such that better candidates appear on top of the result list. eDiVA has
been developed with specific emphasis on usability, automation, and
reproducibility of results and is available as a web service with a graphical
user interface (see Supporting Information Material), or as an open‐
source repository with Docker containers. eDiVA can be run using the
NextFlow (Di Tommaso et al., 2017) pipeline management system to
ensure its compatibility with most standalone or cloud‐computing
platforms as well as to guarantee reproducibility on any system.
eDiVA has been optimized for two common clinical diagnostics
scenarios, parent–child trios comprised of healthy parents and one
affected child (tested for recessive, compound heterozygous, and X‐
linked inheritance or dominant de novo variants) and families with
multiple affected relatives (additionally tested for dominant inheri-
tance). We demonstrate that eDiVA outperforms competing approaches
in a semisynthetic benchmark study introducing thousands of known
disease variants from ClinVar (Landrum et al., 2014) or HGMD (Stenson
et al., 2017) into real WES data from the 1000 Genomes Project CEPH
parent–offspring trio of European ancestry (NA12878, NA12891, and
NA12892). We, furthermore, report summary statistics on eDiVA and
Phen–Gen results for 35 unreported disease cases, composed of 15
cases of spinocerebellar ataxia, 16 cases of primary immunodeficiency,
and four cases of congenital myasthenia.
2 | MATERIALS AND METHODS
2.1 | eDiVA pipeline
eDiVA consists of a Python pipeline combined with an SQL Database
back‐end composed of four components: variant prediction, variant
annotation, pathogenicity estimation, and variant prioritization
(Figure S1). The main functionality of eDiVA is to process next‐
generation sequencing (NGS) data for small sets of samples (e.g.,
families or parent–child trios) and to output a shortlist of potentially
causal variants for the diagnosed disease. eDiVA is available as an open‐
source repository, https://github.com/mbosio85/ediva, with a Docker
container composition wrapped within a NextFlow (Di Tommaso et al.,
2017) interface to guarantee exact reproducibility on the most common
computing platforms (including several cloud platforms) and as a freely
accessible web server: http://www.eDiVA.crg.eu. The modular nature of
eDiVA allows for easy integration of specific parts, for example, the
eDiVA‐Score module for pathogenicity estimation, in other pipelines or
tools. Comprehensive examples for the use of eDiVA and example input
files are included in the repository and on the website.
2.2 | eDiVA‐Predict: WES or WGS processing and
variant calling
The eDiVA‐Predict module performs sample‐wise variant calling
according to the recent GATK (McKenna et al., 2010) best practices
(https://www.broadinstitute.org/gatk/guide/best‐practices as of June
2017) to extract genetic variants from raw reads. Reads in fastq
format are aligned using bwa‐mem (H. Li, 2013), alignments are post‐
processed using samtools (H. Li, 2011), GATK (McKenna et al., 2010),
Picard (Picard Tools—By Broad Institute), and custom quality filters
(details provided in Supporting Information Material). Finally, VCF
files are generated using GATK HaplotypeCaller. Subsequent
regenotyping of all positions harboring a single‐nucleotide variant
(SNV) or small insertions and deletions in at least one family member
yields a complete matrix of variants for the whole sample set (family)
in multisample VCF format. Due to the computational resources
required for read alignment and variant calling, eDiVA‐Predict is
currently not enabled on the eDiVA web server, but can be used with
the standalone version of eDiVA on a local or remote computing
infrastructure (e.g., Amazon Cloud). Alternatively, variant prediction
can be performed using any tool able to produce one multisample
VCF file reporting genotype quality and coverage information for all
variable positions (e.g., GATK, McKenna et al., 2010; freebayes,
Garrison & Marth, 2012).
2.3 | eDiVA‐Annotate: Functional variant
annotation
Using the eDiVA‐Annotate module each variant is individually
linked with public information sources to integrate multiple
knowledge domains, and to provide a comprehensive annotation
profile. First, ANNOVAR (Wang et al., 2010) is applied to relate
each variant to its corresponding gene (choosing among UCSC,
Ensembl, or Refseq gene annotations), and to its functional
consequence at the protein level. Next, functional, population
genomics, and evolutionary data relevant for variant prioritization
are added to each variant. To this end we created a MySQL
database, eDiVA‐DB, containing all relevant positional information
obtained from UCSC table browser (Rhead et al., 2010) and other
sources. Each variant is annotated with population allele fre-
quency information from the dbSNP (Sherry et al., 2001),
discovEHR (Dewey et al., 2016), 1000 Genomes Project
(1000GP; The 2015 Genomes Project Consortium, 2015), Exome
Variant Server (Exome Variant ), and GnomAD exomes (Lek et al.,
2016) databases. The latter three databases also provide informa-
tion on specific populations (e.g., Caucasian, Asian, African
American, etc.), which can be selected for improved causal variant
prioritization. Information on evolutionary conservation is incor-
porated from PhyloP (Rhead et al., 2010), and PhastCons (Hubisz,
Pollard, & Siepel, 2011), including conservation scores for
primates, mammals, and vertebrates. Precalculated scores for
functional impact of variants have been integrated based on the
algorithms SIFT (Kumar, Henikoff, & Ng, 2009), PolyPhen‐2
(Adzhubei et al., 2010), Mutation Assessor (Reva, Antipin, &
Sander, 2011), Condel (González‐Pérez & López‐Bigas, 2011),
Eigen (Ionita‐Laza et al., 2016), and CADD (Kircher et al., 2014).
Furthermore, eDiVA‐DB includes information on genomic features
like segmental duplications and simple sequence repeats provided
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by UCSC table browser (Rhead et al., 2010). Finally, eDiVA‐DB
provides clinical data from ClinVar (Landrum et al., 2014) and
OMIM related to each variant and affected gene.
eDiVA‐Annotate uses multisample VCF files and returns a file
with annotated variants in comma‐separated value format. This step
can be performed on the eDiVA web server.
2.4 | eDiVA‐Score: Estimating variant
pathogenicity
eDiVA's prioritization algorithm relies on accurate estimation of
pathogenicity for each variant. We therefore developed eDiVA‐
Score, a machine learning classifier, which assigns a pathogenicity
probability to each variant based on its annotation characteristics
obtained from eDiVA‐Annotate. eDiVA‐Score is built by training a
random forest (RF) model using the R “randomForest” package
with 1000 binary classification trees (Breiman, 2001; Hastie,
Tibshirani, & Friedman, 2009) and five‐fold cross validation. Eleven
features were selected to train the RF model: (a) the maximum
minor allele frequency (MAF) of 1000Genomes and GnomAD
databases; (b) four conservation measures (conservation in
primates and mammals using the PhastCons (Hubisz et al., 2011)
and PhyloP (Pollard, Hubisz, Rosenbloom, & Siepel, 2010); (c) four
functional impact predictors: Condel (González‐Pérez & López‐
Bigas, 2011), Phred‐scaled CADD score (Kircher et al., 2014),
Eigen (Ionita‐Laza et al., 2016), and Mutation Assessor (Reva et al.,
2011); (d) the likelihood to be in a segmental duplication, which
correlates with false‐positive variant calls (Ho, Tsai, Chen, & Lin,
2011); and (e) an in‐house estimator of systematic sequencing
errors called ABB‐score (Muyas et al., 2019). Note that Condel,
Eigen and CADD are combination scores integrating several
features also included in eDiVA‐score, namely evolutionary
conservation (PhastCons and PhyloP in mammals and primates)
and Mutation Assessor scores. The RF model has been trained
using 15,000 random pathogenic and likely pathogenic variants
from the ClinVar database (Landrum et al., 2014) as positive cases.
We then built a control set composed of 15,000 nonpathogenic
variants from ClinVar, and 100,000 random variants from
GnomAD (Lek et al., 2016) not contained in ClinVar. The vast
majority of variants in both positive and negative training set are
rare (allele frequency [AF], <1%; Figure S2a,b), thus circumventing
that AF dominates the classification model. Following the neutral
theory of molecular evolution (Kimura, 1983) missing data is
generated using expected values for nonpathogenic (neutral)
variants (Figure 1). The only exception is AF, as missing data in
the context of AF means that the SNV is novel, that is, has AF of
zero. Variants used for training of the RF have been excluded in all
benchmarking tests performed in this study.
2.5 | eDiVA‐Prioritize: Causal variant prioritization
Causal variant prioritization consists of four steps, (a) ranking by
estimated probability of variants to cause a phenotypic change
(eDiVA‐Score, see above); (b) removal of all variants that do not
segregate according to the selected inheritance mode; (c)
filtering based on functional and population genomic features;
and (d) prioritization based on user defined clinical phenotypes
(as HPO IDs). Filtering based on segregation requires the user to
submit a simple pedigree file defining the relationship between
samples and their disease state (i.e., affected or unaffected), and
to choose the most likely inheritance pattern for the disease (or
to run all modes). eDiVA‐Prioritize can process variants following
five types of inheritance patterns: (a) dominant de novo, (b)
autosomal dominant inherited, (c) autosomal recessive homo-
zygous, (d) autosomal recessive compound heterozygous, or (e)
X‐linked.
Optionally, eDiVA removes variants that are improbable of
being damaging, are likely false‐positive calls or do not have
sufficient read coverage in all family members to reliably
estimate segregation patterns. By default, eDiVA applies a
lenient filter setting defined in Table S1. Finally, eDiVA allows
the user to specify a list of HPO terms (Köhler et al., 2014)
relevant for the disease as an additional source of information to
prioritize variants in genes. eDiVA highlights all variants in genes
related to the submitted phenotypic traits using a custom
algorithm to estimate the HPO‐gene association (detailed in the
Supporting Information material).
2.6 | Performance evaluation using semisynthetic
cases
To assess the performance of eDiVA and several competing methods,
we implemented a semisynthetic benchmark based on real WES data
from a trio in which we spiked‐in known pathologic variants from the
ClinVar database (Landrum et al., 2014). We chose a publicly available
CEPH trio sequenced within the framework of the 1000 Genomes
Project composed of samples with European ancestry NA12878
(daughter), NA12891 and NA12892 (parents), downloadable from
https://public_docs.crg.es/sossowski/MicrobeGenomes/human/eDiVA/
insilico_simulation_data/, and we called variants and generated a
multisample VCF file using eDiVA‐Predict. For the purpose of this
benchmark study, all 138,705 variants found in the original trio are
considered true negatives, that is, variants not associated with the
disease.
Next, we embedded known disease variants in the trio following
segregation patterns expected for Mendelian diseases. This positive
set, containing variants associated with the diseases, consists of all
variants from ClinVar (Landrum et al., 2014) database labeled as
“pathogenic” or “likely pathogenic”, having an OMIM reference in the
database and that had not been used for training of eDiVA‐Score. For
each pathogenic variant, we extracted: chromosome, position,
reference and alternative nucleotides, dbSNP identifier, gene name,
inheritance mode of the associated disease (where available,
randomly assigned otherwise), and HPO terms for the disease.
Variants without HPO annotation have been excluded from the
benchmark set.
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We have simulated three inheritance patterns: autosomal
recessive homozygous, autosomal recessive compound heterozygous,
and dominant de novo, as these are the most likely patterns found in
parent–child trio based rare‐disease diagnostics. To create realistic
disease genotypes, each pathogenic variant was introduced into the
exomes of the daughter and the parents, if applicable according to
the inheritance mode. The read distribution of reference and
alternative reads was simulated depending on the inheritance mode
and the original coverage data. The variant allele frequency (VAF) of
the alternative allele (i.e., the fraction of reads showing the
alternative allele) introduced in the original VCF file has been
obtained using a beta distribution and a binomial distribution for
homozygous and heterozygous variants, respectively. A total of 6,811
disease‐associated variants from ClinVar not previously used in the
training of eDiVA‐Score were used for benchmarking: 3,353
recessive homozygous, 2,592 dominant de novo, and 866 recessive
compound heterozygous disease‐causing variants (see Table S2 for
additional information on simulated genotypes).
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2.7 | Benchmarking of variant pathogenicity
estimation methods
We evaluated the ability of eDiVA‐Score and six competing methods,
namely CADD, Eigen, DANN, Revel, M‐CAP, and MetaLR (Dong et al.,
2015, Ioannidis et al., 2016, Ionita‐Laza et al., 2016, Jagadeesh et al.,
2016, Kircher et al., 2014, Quang, Chen, & Xie, 2015), to prioritize
pathogenic over benign variants. We generated a receiver operating
characteristic (ROC) curve for each tool and benchmark set and
measured performance by area under the curve (AUC).
First, we evaluated the performance of each method on the
ClinVar test set (containing only variants not used for model
training), using variants labeled “pathogenic” as true positives (TP)
and variants labeled “benign” as true negatives (TN; Figure 2a–c).
Second, we benchmarked using variants from the HGMD and
GnomAD databases (not used in model training or present in
ClinVar) as TP and TN, respectively (Figure 2d–f). Third, we
measured the performance of all methods on HGMD data only,
using the categories for damaging and likely damaging mutation (DM
and DM?) as TP and any other HGMD category as false positives (FP)
(Figure 3g–i). Functional impact values for the benchmarked methods
have been obtained from the respective publications. CADD, DANN,
and eDiVA provide damage estimates for all positions of the genome,
and Eigen for close to 70% of all positions, whereas Revel, M‐CAP,
and MetaLR are trained specifically for rare (AF, <1%) or known
variants and are only available for a subset of ClinVar, HGMD, and
GnomAD. We, therefore, performed three separate performance
tests for each of the three benchmark sets, applying the following
criteria (a) using only variants having Revel and M‐CAP scores
available (ClinVar: 3,887 TP and 10,494 TN; HGMD/GnomAD:
63,712 TP and 100,000 TN; HGMD: 63,712 TP and 1,892 TN); (b)
random subset of all variants, assigning a default value of 0 to missing
values (ClinVar: 19,888 TP and 16,694 TN; HGMD/GnomAD: 96,569
TP and 100,000 TN; HGMD: 96,569 TP and 7376 TN); and (c) using
only rare variants (AF, ≤0.01) from the previous pool of variants
(ClinVar: 16,531 TP and 15,531; HGMD/GnomAD: 90,004 TP and
97,828 TN; HGMD: 96,004 TP and 2,817 TN).
Furthermore, we studied five variant sets provided by Grimm
et al. (2015), forming a collection of data sets for benchmarking
pathogenicity classifiers published in independent studies. Finally, we
combined these five sets to form a combined benchmark (see
Supporting Information Materials for details).
2.8 | Benchmarking of disease variant
prioritization methods
We compared eDiVA with three commonly used tools for variant
annotation and prioritization: Exomiser (Robinson et al., 2014),
PhenoDB (Sobreira et al., 2015), and Phen–Gen (Javed et al., 2014)
on a set of 6,811 semisynthetic parent–child trios (see above).
PhenoDB was executed from the https://phenodb.org/ website using
standard parameters (a) AF, <0.01; (b) including variants which are
present in dbSNP, and (c) analysis type chosen among “autosomal
recessive compound heterozygous”, “autosomal recessive homozy-
gous”, or “autosomal dominant new mutation”. We locally installed
Phen–Gen and launched it with the corresponding setups: (a)
“Recessive”, “allow_de_novo = 0” for recessive and compound inheri-
tance, and (b) “Dominant”, “allow_de_novo = 1” for the dominant de
novo inheritance model. We locally installed Exomiser and analyzed
all trio cases using PhenIX prioritization mode (details in Supporting
Information Material). We tested eDiVA in two configurations, (a)
without phenotype description, and (b) using HPO IDs describing the
disease phenotype for disease‐specific prioritization of candidate
variants.
To benchmark the ability of eDiVA, Exomiser, PhenoDB, and
Phen–Gen to distinguish disease‐causing from benign variants we
compared three quality metrics, (a) recall (i.e., did the causal variant
appear in the output list or not), (b) average number of false positives
across all benchmarked cases as a proxy for precision, and (c) ranks
of causal variants reported for each mode of inheritance using violin
plots (Figure 3a–c). To compare ranks, variants reported by eDiVA
are sorted by eDiVA‐Score, Phen–Gen results are sorted by DCOD‐
score (“Probability of deleteriousness based on genic predictor”), and
Exomiser results are sorted by “Exomiser Gene Combined Score”.
Results of PhenoDB are presented in the default order (chromosome
and position), as no prioritization score is provided.
3 | RESULTS
3.1 | eDiVA: A platform for pathogenicity
estimation and causal variant prioritization
eDiVA is a disease variant prioritization tool optimized for NGS‐
based genetic disease diagnostics in families and parent–child trios. It
is composed of four components: eDiVA‐Predict handles read
alignment and variant prediction, eDiVA‐Annotate performs func-
tional annotation of variants, eDiVA‐Score estimates the probability
of variants to be pathogenic, and eDiVA‐Prioritize filters and ranks
variants according to various quality criteria, proper segregation, and
likelihood to cause phenotypic changes. eDiVA is available as
standalone software at https://github.com/mbosio85/ediva, and as
a web service providing access to functional annotation, pathogeni-
city classification and causal variant prioritization modules (www.
ediva.crg.eu). The eDiVA web service facilitates analysis of families or
parent–child trios in a few clicks, requiring only a VCF file, and
optionally a set of HPO IDs describing the disease phenotype. eDiVA
returns a shortlist of candidate variants and genes, ranked by
pathogenicity score (together with gene relatedness to the specified
HPO IDs if available), and including all annotation features in comma‐
separated value (.csv) and Microsoft Excel (.xlsx) format.
3.2 | Benchmarking eDiVA and competing methods
To comprehensively evaluate eDiVA's performance in finding
disease‐causing variants, and to compare it to previously published
tools, we performed a benchmark in two categories. First, we
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F IGURE 2 Benchmarking of the pathogenicity classifiers eDiVA‐Score, CADD, Eigen, Revel, and M‐CAP using ROC for (a) set of 10,494
ClinVar pathogenic variants (TP) and 3,887 ClinVar “benign” variants (TN); (b) set of 16,694 ClinVar pathogenic variants (TP) and 19,888
ClinVar “benign” variants (TN), setting missing values to benign, (c) subset of rare variants (AF, <1% from set c); (d) set of 63,712 variants from
HGMD (TP) and 100,000 from GnomAD (TN) for which values from all tools are available; (e) set of 96,569 variants from HGMD (TP) and
100,000 from GnomAD (TN), setting missing values to benign; (f) subset of rare variants (AF, <1% from set e); (g) set of 63,712 HGMD variants
(“DM” and “DM?”) as TP, and 1,892 HGMD variants (other categories) as TN for which values from all tools are available; (h) set of 96,569
variants from HGMD (“DM” and “DM?”) as TP, and 7,376 HGMD (other categories) as TN, setting missing values to benign; and (i) subset of rare
variants (AF, <1% from set h). AF: allele frequency; eDiVA: exome Disease Variant Analysis; M‐CAP: Mendelian clinically applicable
pathogenicity; ROC: receiver operating characteristic; TN: true negative; TP: true positive
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evaluated the ability of eDiVA‐Score to distinguish disease‐causing
from benign variants compared to four publicly available methods for
estimating deleteriousness. Second, we benchmarked the perfor-
mance of eDiVA, PhenoDB, and Phen–Gen on identification of causal
variants using semisynthetic parent–child trios analyzed by WES,
optionally allowing for the use of clinical phenotype descriptions for
causal variant prioritization.
3.3 | Benchmarking of eDiVA‐Score and other
variant pathogenicity classifiers
We developed eDiVA‐Score, a machine learning‐based method for
estimating variant pathogenicity (deleteriousness) independent of
any prior clinical information (see Section 2). Feature‐selection
identified population allele frequency, functional impact, and con-
servation in placental mammals as the most important features
(Figure 1a). The correlation matrix for all features is shown in
Figure S3. Features selected for inclusion in the RF show distinct
distributions for pathogenic variants compared to benign variants in
ClinVar (Figure 1b), random coding variants reported in GnomAD
(Figure S4b). All integrated conservation scores (PhyloP and
PhastCons scores for vertebrates, mammals and primates) classify
pathogenic variants better than random, but perform worse than any
specialized method for estimating functional impact or pathogenicity
(Figure S5).
We benchmarked the ability of eDiVA‐Score, CADD, DANN,
Eigen, Revel, M‐CAP, and MetaLR to predict the deleteriousness of
variants and to distinguish pathogenic from benign variants in nine
setups (Section 2). We first compared the performance on classifying
pathogenic and benign variants from ClinVar (Figure 2a), on
distinguishing disease variants from HGMD (Stenson et al., 2017)
from 100,000 random variants from GnomAD (Figure 2d), for which
scores are available for all methods. Note that Revel and M‐CAP
have been trained on a subset of the HGMD variants (e.g., using class
“DM” as positive training set), giving them an advantage due to
potential overfitting in any of the following benchmark tests using
HGMD variants (for an in‐depth discussion of the interplay between
overfitting and circularity in training and benchmarking data (Grimm
et al., 2015). Using ROC analysis, we found that eDiVA‐Score
distinguishes disease‐causing and benign variants with high sensitiv-
ity and recall in both benchmark sets (AUC of 0.95 and 0.90),
considerably better than CADD (AUC of 0.91 and 0.74), DANN (AUC
of 0.89 and 0.82), Eigen (AUC of 0.87 and 0.77), Revel (AUC of 0.91
and 0.89), M‐CAP (AUC of 0.84 and 0.90), and MetaLR (AUC of 0.88
and 0.87). Of note, eDiVA‐Score showed better precision‐recall
curves than competing methods (Figure S6).
F IGURE 3 Receiver operating characteristic curves comparing pathogenicity classifiers on five independent data sets (and the combined set)
composed of pathogenic and neutral variants. Revel, M‐CAP, and eDiVA show a similarly strong performance, with the exception of the
PredictSNP and Varibench sets, on which Revel and M‐CAP outperform eDiVA‐Score. eDiVA: exome Disease Variant Analysis; M‐CAP:
Mendelian clinically applicable pathogenicity; SNP: single‐nucleotide polymorphism
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Disease variant prioritization tools depend on pathogenicity
values for any position of the exome, since de novo mutations can
occur randomly and novel ultra‐rare variants are still being
discovered. Therefore, we next benchmarked the methods on
random variants chosen from the complete ClinVar and HGMD/
GnomAD benchmark sets, whereas setting missing data to benign
(Section 2). As expected, the recall of Revel, M‐CAP, and MetaLR
decreased substantially due to missing information, whereas the
other methods performed slightly better than in the previous tests
(Figure 2b,e). Finally, we tested how the methods perform on
classification of rare variants (AF, <0.01), otherwise following the
same criteria for selection of the test sets as in the previous
benchmark (Figure 2c,f). Again, eDiVA‐Score shows the best
performance of all methods.
We wondered if the use of random GnomAD variants as TN
(nonpathogenic) set might bias the results of the HGMD/GnomAD
benchmark due to for example, overfitting onto the allele frequency
feature. Therefore, we next measured the performance of all
methods on HGMD data only, using the categories for highly likely
pathogenic (“DM” and “DM?”) as TP set and less likely pathogenic
(any other HGMD category) as TN set (Section 2). We performed the
same three tests as discussed above for the ClinVar and HGMD/
GnomAD benchmark sets. On the subset of variants for which scores
are available for all methods (Figure 2g) eDiVA's performance (AUC
0.77) was found to be slightly lower than MetaLR's (0.80), Revel's
(AUC 0.82), and M‐CAP's (AUC 0.85), but substantially better than
the performance of the other general‐purpose methods CADD (AUC
0.67) and Eigen (AUC of 0.70). However, eDiVA still outperformed all
other methods on the complete HGMD variant set (missing scores
set to benign), as well as on the rare variant set (Figure 2h,i).
Finally, we compared the performance of all methods on a
benchmark set compiled by Grimm et al. (2015), consisting of
mutually exclusive subsets of the previously published benchmark
sets Varibench, HumVar, ExoVar, predictSNP, and SwissVar (see
Supporting Information Material for details). These popular bench-
mark data sets differ in the way they define pathogenic and neutral
variants, for example, the maximum AF for pathogenic variants can
differ dramatically, allowing us to benchmark diverse challenges.
Furthermore, Grimm et al. filtered these benchmark sets to minimize
overlap between them, reducing the likelihood that tools are
benchmarked on variants they have been trained on and hence
reducing the impact of overfitting on the benchmark results (Grimm
et al., 2015). We found that none of the methods consistently
performs better than other methods, but that eDiVA‐Score, M‐CAP,
Revel, and MetaLR show comparably high performance, except on
PredictSNP and Varibench, for which MetaLR, Revel, and M‐CAP
show a better performance than eDiVA‐Score. PredictSNP incorpo-
rates HGMD variants in the positive and negative control sets; see
Tables 2 and 3 of Grimm et al. (2015), likely to be giving a strong
advantage to Revel and M‐CAP, which have been trained on HGMD.
CADD, DANN, and Eigen performed significantly worse than the
other three methods on all benchmark sets. Note that CADD, DANN,
Eigen, and MetaLR have been trained to predict deleteriousness (or
more general the functional impact) of variants, whereas eDiVA‐
Score, Revel, and M‐CAP have been trained to identify pathogenic
variants, partly explaining the divergent performance levels across
the different benchmark sets. Moreover, eDiVA‐score, MetaLR, and
M‐CAP use CADD as one of many features, explaining the better
performance of the derived scores.
In summary, our benchmark results demonstrate the good
performance of eDiVA‐Score as pathogenicity classifier, comparable
to and often better than state‐of‐the‐art methods available to date.
Furthermore, eDiVA‐Score outperforms other general‐purpose
methods not restricted by variant AF (i.e. CADD, DANN, and Eigen),
while showing competitive results when compared with specialized
tools such as MetaLR, M‐CAP, and Revel, which are only available for
known (rare) SNVs.
3.4 | Causal variant prioritization in parent–child
trios
We benchmarked the performance of eDiVA and three widely used
tools, PhenoDB, Phen–Gen, and Exomiser, on identification of causal
variants for rare Mendelian diseases in parent–child trios. To this
end, we simulated three scenarios typically encountered in parent–
child trio diagnostics, (a) autosomal dominant de novo, (b) autosomal
recessive homozygous, and (c) autosomal recessive compound
heterozygous Mendelian inheritance modes. In total, we simulated
6,811 semisynthetic parent–child trios by integrating reported
pathogenic variants from ClinVar into real WES data of a trio
obtained from 1000GP (see Section 2 and Table S2).
Figure 3a shows violin plots with the rank distribution of causal
variants in the output lists of 6,811 analyzed trios. The optimal result
is a skewed distribution close to zero, meaning that the causal variant
is reported as first or very close to the top of the list in the majority
of cases. Here, comparison with PhenoDB is not meaningful, as
PhenoDB (unlike Phen–Gen, Exomiser, and eDiVA), offers no ranking
based on pathogenicity scores (but sorts by chromosome and
position). Compared to Exomiser and Phen–Gen, eDiVA's ranking
method shows the best performance for recessive homozygous
inheritance, eDiVA and Exomiser show best performance for
dominant de novo inheritance, and all tools show similarly good
performance for compound heterozygous inheritance. eDiVA con-
sistently reported causal recessive homozygous variants and com-
pound heterozygous variants within the top five candidates
(median = 1), and dominant de novo variants within the top 25 of
reported candidates (median = 4; Figure 4a). Considering that the
CEPH trio has been sequenced as part of the 1000GP we finally
tested if the use of 1000GP allele frequency information for filtering
biases the performance estimates of eDiVA. However, we found no
difference when not using the 1000GP AF database (Figure S7).
Nonetheless, we cannot exclude the possibility that eDiVA (or the
other methods) show reduced performance in understudied popula-
tions.
The use of HPO IDs for prioritization further reduced FPs
reported by eDiVA (label eDiVA‐HPO in Figure 4c). Overall, we
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observed a two‐fold reduction in FPs across all inheritance modes
tested. However, filtering by in silico gene panels also resulted in a
reduction in recall (Figure 4b,c). Finally, we observed improved
prioritization ranks under all inheritance types, with the strongest
impact seen for de novo variants (Figure 4a).
We also investigated the impact of incomplete or imperfect
phenotyping on eDiVA's performance by altering the HPO annota-
tion of genetic variants imported from ClinVar (see Supporting
Information Methods). Benchmarking results on the semisynthetic
simulation with incomplete phenotyping show a small reduction in
causal gene ranking efficiency (Figure S8). However, even imperfect
phenotypic information improved the performance as compared to
complete exclusion of such information.
In summary, the benchmark analyses show that eDiVA achieves
highly competitive causal variant prioritization performance with
respect to ranking, precision and recall, while requiring no fine tuning
of parameters by the user for specific inheritance types. When
disease‐specific HPO term descriptors are available, eDiVA's
(a)
(b)
(c)
F IGURE 4 Benchmark of the causal variant prioritization tools eDiVA, Exomiser, Phen–Gen, and PhenoDB. (a) Violin plots showing the rank
of disease‐causing variants within the reported candidate lists for the three tested inheritance types: “recessive homozygous”, “compound
heterozygous”, and “dominant de novo”; (b) Recall values for 6,811 semisynthetic trio cases, representing the fraction of identified causal
variants (i.e., “solved cases”). (c) Average number of false positives reported per case as a proxy for precision. eDiVA has been tested in two
configurations, with HPO‐based gene prioritization (eDiVA_HPO) and with the default configuration not using HPO terms (eDiVA). Adding HPO
filtering reduces false positives at the cost of a slightly reduced Recall. HPO: Human Phenotype Ontology
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precision is further enhanced to the point at which complete
automation of causal variant identification is feasible for recessive
homozygous and compound heterozygous segregation.
3.5 | eDiVA results on clinical cases
eDiVA has successfully been used in published case studies on mitral
valve prolapse (Durst et al., 2015), cystic fibrosis (Ramos et al., 2014),
phenylketonuria (Trujillano et al., 2014), arthrogryposis (Wambach
et al., 2017), and Opitz‐C (Urreizti et al., 2017), among others,
identifying both known, as well as novel rare‐disease genes. We
recently assessed the performance of eDiVA for the diagnosis of rare
congenital genetic diseases using WES of 35 parent–child trios,
including 15 cases of congenital ataxia, four cases of congenital
myasthenia, and 16 cases of primary immunodeficiency. Here we
report general statistics on the number of candidate genes per case,
while case reports and novel candidate genes will be published in
separate papers. Across the 35 studied trios, eDiVA on average
reported a median of 11, 3, and 10 candidate genes per trio for
recessive homozygous, recessive compound heterozygous, and
dominant de novo inheritance mode, respectively, using default
parameters. In comparison, Phen–Gen reported a median of 36 and
52 candidate genes for recessive (including compound heterozygous)
and dominant (including de novo) inheritance mode, respectively.
Histograms of reported candidate gene numbers for eDiVA and
Phen–Gen are shown in Figures S9 and S10. eDiVA found causal
variants in known genes for the respective disease in none cases, and
variants in genes associated with closely related disease phenotypes
in seven cases. Screening of Phen–Gen results did not reveal
additional candidates missed by eDiVA. The function of a novel
disease variant for congenital ataxia has been described in
Bahamonde et al. (2015), and reports for other candidate genes are
in preparation.
4 | DISCUSSION
Despite the massive increase in sequencing capacity and the
availability of highly optimized analysis tools, multiple large‐scale
rare‐disease studies reported that in only 20–30% of cases a causal
variant can be identified using WES. Several reasons might explain
the inability of WES analysis to identify causal variants in a majority
of cases, including for example, the inability to identify regulatory
variants (Claussnitzer et al., 2015), our limited knowledge of the
function of noncoding RNAs, generation of new exon donor or
acceptor sites by intronic variants (Y. Lee et al., 2012), small copy
number variations (Krumm et al., 2012), incomplete penetrance, and
unknown function of coding genes, among others. However, we argue
that the potential of WES has not been exhausted and that causal
coding variants are often missed due to inappropriate correction of
noise in the data, insufficient use of clinical (phenotypic) data, or
reporting of long unranked candidate lists, requiring tedious screen-
ing by clinicians. We further claim that these shortcomings are often
overlooked due to unrealistic simulated benchmark tests not
reflecting the level of noise found in real family or trio NGS data.
We have addressed these problems by developing eDiVA, a
pipeline that combines multisample variant calling of family data, QC
and filtering, extensive functional annotation, machine learning‐
based classification of deleterious variants, and prioritization of
causal variants optimized for various clinical scenarios. Furthermore,
we developed a highly realistic benchmark test combining real WES
data of a parent–child trio with thousands of pathogenic ClinVar
variants to generate 6,811 semisynthetic disease trios. Using these
cases, we have demonstrated that eDiVA's pathogenicity estimator
(eDiVA‐Score) as well as eDiVA's prioritization algorithm perform
favorably compared to existing state‐of‐the‐art methods. eDiVA has
been able to find disease‐causing variants with higher recall, fewer
false positives and better ranking than competing tools in three
benchmarked modes of inheritance. Finally, we evaluated the use of
phenotypic descriptors for optimizing the prioritization process.
We found that adding HPO ID‐based prioritization introduces a
trade‐off between recall and the number of false positives in the
output list. Despite the marginal reduction in recall, focusing on
known disease genes is often the preferred choice for diagnostic
purposes. Our knowledge of genetic factors playing a role in disease
is constantly growing, reflected in a rapid increase of genotype–
phenotype relations stored in various databases. Hence, it would be
beneficial to reanalyze WES data sets once in a while (e.g., every
6–12 months) to benefit from new knowledge and to facilitate
identification of previously unknown/unreported causal variants.
Moreover, combined reanalysis of the growing cohorts of WES data
stored in many institutes would allow to identify matching causal
genes across multiple families or cases. However, most analysis
pipelines require substantial hands‐on time and long candidate‐
variant lists have to be screened by experts, making regular
reanalysis of data sets impractical. eDiVA has been developed with
a specific emphasis on high reproducibility of results and complete
automation of the analysis using artificial intelligence‐based methods.
Machine learning classifiers are used to perform candidate ranking
and prioritization, reducing hands‐on time of clinical experts to a
minimum. Integration with NextFlow, moreover, guarantees repro-
ducibility of results at later time points and on most computing
platforms. Therefore, eDiVA is a dedicated solution for regular
reanalysis of large disease cohorts or collections of diagnostic cases.
Additional steps can be taken to improve the identification of
disease‐related variants fromWES data. The availability of custom allele
frequency databases with geographical specificity would help to reduce
the number of false‐positive genotype–phenotype associations due to
population specific variants. To this end, institutes and hospitals with
access to large cohorts of sequenced exomes may use in‐house data to
filter population specific variants, an approach we have pursued our self
by collecting thousands of Iberian cases in an aggregated allele
frequency database (http://geevs.crg.eu/, unpublished). Identification
of extended homozygosity regions could in addition help to diagnose
causal homozygous variants in consanguineous cases. Moreover, the
integration of structural and copy number variants (SVs and CNVs) has
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been shown to increase recall rates substantially (Gambin et al., 2017).
Despite their frequent involvement in rare diseases (McCarroll &
Altshuler, 2007), CNVs are often disregarded in WES analyses, and are
rarely processed in combination with point mutations. Prioritization
algorithms will have to be adapted to consider compound heterozygotes
composed of a point mutation in one and a CNV in the other allele. CNV
analysis is currently being integrated in eDiVA and will be available in
the near future.
Better use of phenotypic descriptors has the potential to improve
both precision and recall of causal variant prioritization methods. We
observed that HPO ID‐based prioritization dramatically improved
the precision of eDiVA. However, incomplete maps of known
genotype–phenotype (or gene–phenotype) relations in public data-
bases led to a mild reduction in recall. Robinson et al. (2014)
proposed a method to overcome this limitation, tapping into the
genotype–phenotype associations from mouse data to solve causal
variant identification for corresponding human phenotypes. Other
methods based on image analysis, for example, Hadj‐Rabia et al.
(2017) or face2gene (http://suite.face2gene.com/), have also shown
promising results for diagnosis of patients with visible phenotypic
features. Finally, an important step in the evaluation of newly
discovered genotype–phenotype associations is the identification of
additional cases with a similar phenotype and mutations in the same
gene. Several approaches for gene matching have been published, for
example, GeneMatcher (Sobreira et al., 2015), which have been
connected via the Matchmaker Exchange platform. Integration of
approaches using image analysis, cross‐species phenotype–genotype
correlation, and gene matching has the potential to further improve
AI‐based variant prioritization methods such that they can rival the
diagnostic precision of clinical experts in the future.
In summary, we have shown that eDiVA is a step towards full
automation of causal variant identification in family and parent–child
trio data using machine learning‐based approaches. eDiVA can be
used as a support tool for clinicians to find disease‐causing variants,
or as a fully automated solution for periodic reanalysis of large WES
(or WGS) cohorts. eDiVA is able to identify known causal disease
variants with high precision and recall, and facilitates identification of
novel disease variants with minimal hands‐on time.
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